Facebook
Twitter
LinkedIn
ForwardDogmas and Controversies in Hematologic Malignancies: Los Angeles
This CME-accredited activity, Dogmas and Controversies in Hematologic Malignancies: Los Angeles, features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of Hodgkin and non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute leukemias, myeloproliferative neoplasms and multiple myeloma.
The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of recent advances along with scientific debates and panel-based discussions focusing on controversies in the management of hematologic malignancies. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care. This conference will highlight a multidisciplinary approach and the integration of new advances in patient-centered care. Physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals will be updated on the latest updates in Hematologic Malignancies.
Target Audience
- Cancer care professionals
- Medical Oncologists and Hematologists
- Radiation oncologists
- Pathologists
- Medical oncology and hematology fellows
- Oncology nurses
- Nurse practitioners
- Physician assistants
- Pharmacists
Organizing Committee
Conference Director:
Binay Shah, MD, MHA - Binaytara Foundation
Conference Chairs:
Alexey V. Danilov, MD, PhD - City of Hope Medical Center
Thomas G. Martin, MD - UCSF Helen Diller Family Comprehensive Cancer Center
Vinod Pullarkat, MD, MRCP - City of Hope Medical Center
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Review strategies for initial therapy and therapies for relapsed disease for patients with various hematologic malignancies
- Outline efficacy and toxicities of small molecule inhibitors, monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with hematologic malignancies
- Apply an individualized treatment plan for patients with ALL, AML, CML, MPN, MM, NHL, HL, based on patient- and disease-related factors
- Review evolving role of autologous and allogeneic stem cell transplantation in different hematologic malignancies
HOTEL INFORMATION
COMING SOON
GLOBAL ONCOLOGY PROJECT
To learn more about our ongoing project building a 200-bed cancer hospital in Nepal.
DAY 1 - March 28th, 2025
All times listed in Pacific Time Zone (PT)
12:30 PM – 01:30 PM Registration/Networking/Exhibits
01:30 PM – 01:50 PM Plenary Lecture - Next Generation CAR T-Cell Therapeutics
01:50 PM – 02:00 PM Q&A
02:00 PM – 03:30 PM Session 1 - Non-Hodgkin's Lymphoma
Session Chair: Alexey Danilov, MD, PhD
02:00 PM – 02:15 PM Have BTK Inhibitors Replaced Transplant in MCL? - Tycel Phillips, MD
02:15 PM – 02:30 PM DLBCL: Is There Still a Role for Autologous Transplant?
02:30 PM – 02:45 PM DLBCL: Embarrassment of Riches? Post-CAR T Space
Debate: CAR-T versus Bispecifics in FL
02:45 PM – 02:55 PM CAR-T
02:55 PM – 03:05 PM Bispecifics - Swetha Kambhampati Thiruvengadam, MD
03:05 PM – 03:30 PM Case-Based Presentation & Panel Discussion
03:30 PM – 04:00 PM Break & Exhibits
04:00 PM – 05:30 PM Session 2 - Leukemia
Session Chair: Vinod Pullarkat, MD
04:00 PM – 04:15 PM Doublets and Triplets: AML Induction in the Era of Targeted Therapies
04:15 PM – 04:30 PM Menin Inhibitors: Next Best Thing Since Venetoclax?
04:30 PM – 04:45 PM Low Risk MDS: Do New Approved Therapies Change Outcomes? - Brian Ball, MD
04:45 PM – 05:00 PM Case Presentation
05:00 PM – 05:30 PM Panel Discussion
05:30 PM – 06:30 PM Reception/Networking & Poster Abstracts
DAY 2 - March, 29th, 2025
07:00 AM – 08:00 AM Registration, Breakfast, & Exhibits
08:00 AM – 09:30 AM Session 3 - Myeloma
Session Chair:
08:00 AM – 08:15 AM SMM – With All the New Data – Is Treatment More or Less Controversial? - Ajai Chari, MD
08:15 AM – 08:30 AM Frontline Therapy for the “Frail” – How Do We Define Frail and Which Drugs to Combine?
08:30 AM – 08:45 AM What is High-Risk MM? New Definition and Treatment?
Debate: What is Best: Maintenance Therapy or Continuous Therapy for TE and TI MM?
08:45 AM – 08:55 AM Maintenance is Lenalidomide
08:55 AM – 09:05 AM Maintenance Should Include a CD38 Monoclonal Antibody
09:05 AM – 09:30 AM Case-Based Discussion
09:30 AM – 10:00 AM Break & Exhibits
10:00 AM – 11:30 AM Session 4 - Leukemia
Session Chair: Vinod Pullarkat, MD
10:00 AM – 10:15 AM Incorporating Blinatumomab into Frontline ALL Regimens? - Ryan Cassaday, MD
10:15 AM – 10:30 AM CML: Which TKI? For How Long? - Jerald Radich, MD
10:30 AM – 10:45 AM Can CAR T Cure Adult ALL?
Debate: Stem Cell Transplant for Ph + ALL
10:45 AM – 10:55 AM Transplant is Outdated
10:55 AM – 11:05 AM Transplant is Still Standard of Care
11:05 AM – 11:30 AM Panel Discussion
11:30 AM – 11:45 AM Session 5 - Global Oncology
Improving Access to Hematology and Oncology in LMIC - Binaytara Foundation's Approach - Binay Shah, MD, MHA
11:45 AM – 12:30 PM Session 6 - APP Discussion: Treatment Toxicities - Practical Tips on Management
Session Chair:
Panel Discussion:
12:30 PM – 01:30 PM Lunch & Exhibits
01:30 PM – 03:00 PM Session 7 - Myeloma
Session Chair:
01:30 PM – 01:45 PM Current Results With CAR T-cell Therapy - Andrew Cowan, MD
01:45 PM – 02:00 PM Current Results With Bispecific T-cell Engager Antibodies
Debate: RRMM – What is the Best Therapy for Early Relapse MM
02:00 PM – 02:10 PM CAR T-cell Therapy Should Be First Choice for First or Subsequent Relapse
02:10 PM – 02:20 PM CAR T therapy Should Be Reserved for Late Relapse
02:20 PM – 02:35 PM Exciting Agents (non-Immunotherapy) for Triple Class Refractory MM
02:35 PM – 03:00 PM Case-Based Discussion
03:00 PM – 03:30 PM Break & Exhibits
03:30 PM – 05:00 PM Session 8 - CLL/LPL and HL
Session Chair: Alexey Danilov, MD, PhD & Catherine Coombs, MD
03:30 PM – 03:45 PM Do We Still Need Clinical Trials in HL?
03:45 PM – 04:00 PM How I Treat LPL - Geoff Shouse, DO, PhD
04:00 PM – 04:15 PM Evolution of Therapy in Richter's Syndrome - Benjamin Heyman, MD
Debate: CLL Progressing on BTK Inhibitors
04:15 PM – 04:25 PM Stay in Class - Catherine Coombs, MD
04:25 PM – 04:35 PM Switch Class - Mazyar Shadman, MD, MPH
04:35 PM – 05:00 PM Panel Discussion
05:00 PM Adjourn
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Binay Shah, MD, MHA
Alexey Danilov, MD, PhD
Ryan Cassaday, MD
Tycel Phillips, MD
Jerald Radich, MD
Geoffrey Shouse, DO, PhD
Available Credit
- 10.50 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 10.50 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 10.50 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.50 Contact Hours.
If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.
Required Hardware/software
Morbi tristique senectus et netus et malesuada fames ac turpis.